文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

泻药不能改善阿片类药物引起的便秘症状:患者调查结果。

Laxatives Do Not Improve Symptoms of Opioid-Induced Constipation: Results of a Patient Survey.

机构信息

Department of Gastroenterology, University College Hospital, London, UK.

Chronic Pain Policy Coalition (CPPC) Policy Connect, CAN Mezzanine, 32-36 Loman Street, London.

出版信息

Pain Med. 2017 Oct 1;18(10):1932-1940. doi: 10.1093/pm/pnw240.


DOI:10.1093/pm/pnw240
PMID:28339544
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5914325/
Abstract

INTRODUCTION: Laxatives are commonly used to treat opioid-induced constipation, the commonest and most bothersome complication of opioids. However, laxatives have a nonspecific action and do not target underlying mechanisms of opioid-induced constipation; their use is associated with abdominal symptoms that negatively impact quality of life. OBJECTIVE: To assess the effects of laxatives in patients taking opioids for chronic pain. METHODS: One hundred ninety-eight UK patients who had taken opioid analgesics for at least one month completed a cross-sectional online or telephone survey. Questions addressed their pain condition, medication, and laxative use (including efficacy and side effects). The survey also assessed bowel function using the Bowel Function Index. RESULTS: Since starting their current opioid, 134 of 184 patients (73%) had used laxatives at some point and 122 (91%) of these were currently taking them. The most common laxatives were osmotics and stimulants. Laxative side effects were reported in 75%, most commonly gas, bloating/fullness, and a sudden urge to defecate. Side effects were more common in patients less than 40 years of age. Approximately half of patients said laxatives interfered with work and social activities, and one-fifth needed an overnight hospital stay because of their pain condition and/or constipation. Laxatives did not improve the symptoms of constipation, as assessed by the Bowel Function Index. Constipation was not related to opioid strength, dose of opioid, or number of laxatives taken. CONCLUSIONS: Use of laxatives to treat opioid-induced constipation is often ineffective and associated with side effects. Instead of relieving the burden of opioid-induced constipation, laxative use is associated with a negative impact.

摘要

简介:通便剂常用于治疗阿片类药物引起的便秘,这是阿片类药物最常见和最麻烦的并发症。然而,通便剂的作用是非特异性的,不能针对阿片类药物引起的便秘的潜在机制;它们的使用与腹部症状相关,这些症状会对生活质量产生负面影响。 目的:评估通便剂在接受阿片类药物治疗慢性疼痛的患者中的作用。 方法:198 名在过去一个月内服用过阿片类镇痛药的英国患者完成了一项横断面在线或电话调查。问题涉及他们的疼痛状况、药物和通便剂的使用情况(包括疗效和副作用)。该调查还使用肠功能指数评估了肠道功能。 结果:自开始使用当前的阿片类药物以来,184 名患者中有 134 名(73%)在某些时候使用过通便剂,其中 122 名(91%)目前正在使用。最常用的通便剂是渗透性和刺激性的。通便剂的副作用报告发生率为 75%,最常见的是气体、腹胀/饱胀和突然有排便的冲动。副作用在年龄小于 40 岁的患者中更为常见。大约一半的患者表示通便剂干扰了工作和社交活动,五分之一的患者因为疼痛状况和/或便秘需要住院过夜。通便剂并没有改善便秘症状,如肠功能指数评估的那样。便秘与阿片类药物的强度、阿片类药物的剂量或使用的通便剂数量无关。 结论:使用通便剂治疗阿片类药物引起的便秘通常无效,并伴有副作用。通便剂的使用不仅没有缓解阿片类药物引起的便秘的负担,反而与负面影响相关。

相似文献

[1]
Laxatives Do Not Improve Symptoms of Opioid-Induced Constipation: Results of a Patient Survey.

Pain Med. 2017-10-1

[2]
Opioid-induced constipation, use of laxatives, and health-related quality of life.

Scand J Pain. 2016-4

[3]
Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.

Clin Ther. 2015-4-1

[4]
Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and Symptom Burden Over Time.

Pain Med. 2015-8

[5]
Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.

Curr Med Res Opin. 2014-11

[6]
Laxative utilization over time in chronic pain patients with opioid-induced constipation.

Pain Manag. 2016-11

[7]
The Burden of Opioid-Induced Constipation: Discordance Between Patient and Health Care Provider Reports.

J Manag Care Spec Pharm. 2016-3

[8]
The impact of opioid-induced constipation among chronic pain patients with sufficient laxative use.

Int J Clin Pract. 2015-12

[9]
Pathophysiology, diagnosis, and management of opioid-induced constipation.

Lancet Gastroenterol Hepatol. 2018-3

[10]
Laxative co-medication and changes in defecation patterns during opioid use.

J Oncol Pharm Pract. 2019-10

引用本文的文献

[1]
Opioid-induced constipation in internal medicine: recognition and management pathways.

Intern Emerg Med. 2025-8-28

[2]
Timing of Naldemedine Initiation and Occurrence of Diarrhea in Patients Receiving Strong Opioid Analgesics: A Retrospective Study.

Pharmacy (Basel). 2025-3-21

[3]
Naloxegol for the Treatment of Opioid-Induced Constipation in Patients with Cancer Pain: A Pooled Analysis of Real-World Data.

Cancers (Basel). 2025-3-3

[4]
Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials.

Jpn J Clin Oncol. 2025-1-8

[5]
Advancing peristalsis deciphering in mouse small intestine by multi-parameter tracking.

Commun Biol. 2023-12-7

[6]
Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials.

J Pain Res. 2023-2-10

[7]
A Randomized, Controlled Study to Investigate How Bovine Colostrum Fortification of Human Milk Affects Bowel Habits in Preterm Infants (FortiColos Study).

Nutrients. 2022-11-10

[8]
A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation-The NACASY Study.

Cancers (Basel). 2022-2-23

[9]
Opioid-Induced Constipation in Real-World Practice: A Physician Survey, 1 Year Later.

Pain Ther. 2022-6

[10]
Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?

Cancers (Basel). 2021-11-16

本文引用的文献

[1]
Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation.

Pain Med. 2015-12

[2]
Opioid-Induced Constipation.

Pain Med. 2015-10

[3]
Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain.

Am Health Drug Benefits. 2015-4

[4]
Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and Symptom Burden Over Time.

Pain Med. 2015-8

[5]
Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.

Clin Drug Investig. 2015-1

[6]
Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach.

Am J Gastroenterol Suppl. 2014-9-10

[7]
Factors affecting satisfaction with treatment in European women with chronic constipation: An internet survey.

United European Gastroenterol J. 2013-10

[8]
Further validation of the psychometric properties of the Bowel Function Index for evaluating opioid-induced constipation (OIC).

J Med Econ. 2013-10-24

[9]
The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients.

J Int Med Res. 2011

[10]
Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries.

Curr Med Res Opin. 2010-11-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索